Understanding Kenya's New Injectable HIV Prevention Drug, Lenacapavir

Kenya's Ministry of Health is set to introduce a groundbreaking new HIV prevention drug, Lenacapavir, by January 2026.

What Is Lenacapavir?

Lenacapavir (Yeztugo) is the world’s first long-acting injectable drug for HIV prevention. Unlike daily PrEP pills, it only needs to be administered twice a year. It works by targeting HIV’s protective shell (called a capsid), stopping the virus before it can multiply in the body.

Recently endorsed by the World Health Organization (WHO), the drug has shown near-100% effectiveness in clinical trials, especially among young African women and adolescent girls—groups often overlooked in prevention campaigns.

Why Is Kenya Involved?

Kenya has been named among nine early-adopter countries and plans to begin the rollout by January 2026, through the Ministry of Health and NASCOP. This follows a major announcement at the IAS 2025 conference in Kigali, highlighting Kenya’s role in global health innovation.

Let’s Break It Down (So Simple a 10-Year-Old Could Understand)

Imagine needing to take medicine every single day just to stay safe from getting sick — not fun, right? Now imagine getting just two superhero shots a year, and being safe the whole time. That’s what Lenacapavir does.

It’s like a shield for your body. HIV wears armor to sneak in and attack — Lenacapavir messes up that armor. One shot = six months of protection. And that’s why people are calling it a game-changer.

The Science & The Stats

In one major trial with over 2,000 participants, only two people contracted HIV—and none of them were women. The drug’s long-lasting protection makes it especially useful for those who struggle with daily pills or face stigma when accessing PrEP.

The Cost

In high-income countries, Lenacapavir costs up to KSh 6.5 million a year, but thanks to royalty-free licenses, six generic manufacturers are working to make low-cost versions available for around KSh 5,200 per year.

Pros & Cons

Pros:

Only 2 injections per year

 Reduces stigma around daily pill use

 Great for hard-to-reach and high-risk groups

 Near-100% effectiveness

Cons:

Needs to be administered at a health facility

Must confirm HIV-negative status before every dose

Mild injection site reactions reported

 Still new—long-term effects under observation

 What’s Next?

Until local manufacturers ramp up production, Gilead Sciences will supply doses to 18 countries, including Kenya. The Ministry of Health has committed to getting the drug into the hands of those who need it most—especially vulnerable groups.

Experts are calling Lenacapavir “the closest thing we have to an HIV vaccine.” And with Kenya leading the rollout, it just might be the shot that changes everything.